美国一家三级头痛中心对接受奥那博定注射液(onabotulinumtoxinA)预防慢性偏头痛的患者加用氟马尼珠单抗的实际效果:回顾性图表研究

Q3 Medicine Cephalalgia Reports Pub Date : 2024-01-01 DOI:10.1177/25158163241238448
Hsiangkuo Yuan, Fred Cohen, Maurice T. Driessen, L. Krasenbaum, Mario Ortega, Mary Hopkins, M. Marmura
{"title":"美国一家三级头痛中心对接受奥那博定注射液(onabotulinumtoxinA)预防慢性偏头痛的患者加用氟马尼珠单抗的实际效果:回顾性图表研究","authors":"Hsiangkuo Yuan, Fred Cohen, Maurice T. Driessen, L. Krasenbaum, Mario Ortega, Mary Hopkins, M. Marmura","doi":"10.1177/25158163241238448","DOIUrl":null,"url":null,"abstract":"Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM). This was a single-center, retrospective, observational study that assessed treatment response (change over time in monthly headache days [MHD] and pain intensity [PI]) in adult patients with CM receiving fremanezumab as add-on therapy to onabotA for CM prevention. In the study population ( N = 116, age 50.0 ± 13.1, female 85.3%, pre-index onabotA use 46.5 ± 34.2 months) receiving concurrent onabotA and fremanezumab for 17.5 ± 11.6 months, MHD decreased by 3.60 days (95% confidence interval [CI]: −5.26, −1.94, p < 0.001) and PI was reduced by 0.43 (95% CI: −0.77, −0.09, p = 0.012) at the final visit. Statistically significant reductions were seen in both MHD (−4.61, 95% CI: −6.84, −2.39; p < 0.001) and PI (−0.52, 95% CI: −0.84. −0.09; p = 0.017) among patients naïve to mAbs against CGRP or its receptor. No unexpected adverse events were observed. Concomitant fremanezumab and onabotA for CM prevention were effective at reducing the number of MHD and lessening PI, particularly in patients with difficult-to-treat CM who are naïve to mAbs against CGRP or its receptor.","PeriodicalId":9702,"journal":{"name":"Cephalalgia Reports","volume":"131 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study\",\"authors\":\"Hsiangkuo Yuan, Fred Cohen, Maurice T. Driessen, L. Krasenbaum, Mario Ortega, Mary Hopkins, M. Marmura\",\"doi\":\"10.1177/25158163241238448\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM). This was a single-center, retrospective, observational study that assessed treatment response (change over time in monthly headache days [MHD] and pain intensity [PI]) in adult patients with CM receiving fremanezumab as add-on therapy to onabotA for CM prevention. In the study population ( N = 116, age 50.0 ± 13.1, female 85.3%, pre-index onabotA use 46.5 ± 34.2 months) receiving concurrent onabotA and fremanezumab for 17.5 ± 11.6 months, MHD decreased by 3.60 days (95% confidence interval [CI]: −5.26, −1.94, p < 0.001) and PI was reduced by 0.43 (95% CI: −0.77, −0.09, p = 0.012) at the final visit. Statistically significant reductions were seen in both MHD (−4.61, 95% CI: −6.84, −2.39; p < 0.001) and PI (−0.52, 95% CI: −0.84. −0.09; p = 0.017) among patients naïve to mAbs against CGRP or its receptor. No unexpected adverse events were observed. Concomitant fremanezumab and onabotA for CM prevention were effective at reducing the number of MHD and lessening PI, particularly in patients with difficult-to-treat CM who are naïve to mAbs against CGRP or its receptor.\",\"PeriodicalId\":9702,\"journal\":{\"name\":\"Cephalalgia Reports\",\"volume\":\"131 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cephalalgia Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/25158163241238448\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cephalalgia Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25158163241238448","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

在慢性偏头痛(CM)患者中,降钙素基因相关肽(CGRP)通路单克隆抗体(mAb)和奥那博定(onabotulinumtoxinA,onabotA)同时使用可改善治疗反应,而单独使用奥那博定可改善治疗反应。这是一项单中心、回顾性、观察性研究,目的是评估接受fremanezumab治疗的成年偏头痛患者的治疗反应(每月头痛天数[MHD]和疼痛强度[PI]随时间的变化)。在研究人群(N = 116,年龄 50.0 ± 13.1,女性 85.3%,使用奥那博特前指数 46.5 ± 34.2 个月)中,同时接受奥那博特和氟马尼珠单抗治疗 17.5 ± 11.6 个月后,最终就诊时,MHD 减少了 3.60 天(95% 置信区间 [CI]:-5.26, -1.94, p < 0.001),PI 减少了 0.43(95% 置信区间:-0.77, -0.09, p = 0.012)。在未使用抗 CGRP 或其受体 mAbs 的患者中,MHD(-4.61,95% CI:-6.84,-2.39;p <0.001)和 PI(-0.52,95% CI:-0.84,-0.09;p = 0.017)均有统计学意义的明显降低。未观察到意外不良事件。同时使用fremanezumab和onabotA预防CM能有效减少MHD的数量并降低PI,特别是对于那些对抗CGRP或其受体的mAbs不敏感、难以治疗的CM患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study
Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM). This was a single-center, retrospective, observational study that assessed treatment response (change over time in monthly headache days [MHD] and pain intensity [PI]) in adult patients with CM receiving fremanezumab as add-on therapy to onabotA for CM prevention. In the study population ( N = 116, age 50.0 ± 13.1, female 85.3%, pre-index onabotA use 46.5 ± 34.2 months) receiving concurrent onabotA and fremanezumab for 17.5 ± 11.6 months, MHD decreased by 3.60 days (95% confidence interval [CI]: −5.26, −1.94, p < 0.001) and PI was reduced by 0.43 (95% CI: −0.77, −0.09, p = 0.012) at the final visit. Statistically significant reductions were seen in both MHD (−4.61, 95% CI: −6.84, −2.39; p < 0.001) and PI (−0.52, 95% CI: −0.84. −0.09; p = 0.017) among patients naïve to mAbs against CGRP or its receptor. No unexpected adverse events were observed. Concomitant fremanezumab and onabotA for CM prevention were effective at reducing the number of MHD and lessening PI, particularly in patients with difficult-to-treat CM who are naïve to mAbs against CGRP or its receptor.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cephalalgia Reports
Cephalalgia Reports Medicine-Neurology (clinical)
CiteScore
2.50
自引率
0.00%
发文量
17
审稿时长
9 weeks
期刊最新文献
Protocol of a cross-sectional, multicentre and multidisciplinary study describing phenotype and burden of a midfacial segment pain Paranoid psychosis after a single parenteral dose of indomethacin administered for headache diagnosis: A case and review of the literature Extended regular use of kinetic oscillation stimulation (KOS) in refractory chronic migraine: case report of a first, single-subject experience Corrigendum to “Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies” A century of bruxism research in top-ranking medical journals
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1